SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $21,428 | $16,358 | $12,637 | $35,103 |
| - Cash | $29,425 | $3,692 | $5,640 | $8,898 |
| + Debt | $6,187 | $6,419 | $6,783 | $4,669 |
| Enterprise Value | -$1,810 | $19,085 | $13,780 | $30,874 |
| Revenue | $0 | $0 | $0 | $115 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$765 | -$822 | -$778 | -$671 |
| % Margin | – | – | – | -585% |
| EBITDA | $46,254 | -$9,228 | -$4,349 | -$10,538 |
| % Margin | – | – | – | -9,187.7% |
| Net Income | $5,338 | -$10,114 | -$5,197 | -$11,395 |
| % Margin | – | – | – | -9,934.5% |
| EPS Diluted | -0.21 | -1.09 | -0.56 | -1.23 |
| % Growth | 80.7% | -94.6% | 54.5% | – |
| Operating Cash Flow | -$13,050 | -$7,152 | -$7,797 | -$9,271 |
| Capital Expenditures | $0 | $0 | -$0 | -$55 |
| Free Cash Flow | -$13,050 | -$7,152 | -$7,797 | -$9,326 |